Hydroxyurea in Thalassemia Major

Yadav, Alka; Abrol, Pankaj; Singh, Sunita; Singh, Manju; Nanda, Sanjiv

doi:10.14260/jemds/2016/62

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydroxyurea showed no serious side effects in almost all the studies conducted so far, except mild liver or renal impairment observed in a couple of researches [12][13][14][15][16][17][18]. It can be used safely in children as a single oral dose per day and monitored with complete blood count, alanine aminotransferase (ALT), and serum creatinine levels regularly.…”

Section: Discussionmentioning

confidence: 99%

“…Yadav A et al studied the efficacy of hydroxyurea in 25 cases of transfusion-dependent thalassemia-major. Hydroxyurea significantly increased mean hemoglobin levels and reduced the number of transfusions per day with no significant reportable side effects of therapy [ 15 ]. Ghosh d et al studied the effect of hydroxyurea on 49 transfusion-dependent HbE/beta-thalassemia major cases and found significant improvement in the transfusion-free interval [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan

Akram¹,

Khattak²,

Khan³

2022

Cureus

View full text Add to dashboard Cite

BackgroundHydroxyurea is being used effectively in sickle cell anemia and thalassemia intermedia. Its role in transfusion-dependent beta-thalassemia major yet needs to be clearly established. This study has been carried out to assess the efficacy and safety of hydroxyurea as adjuvant therapy in pediatric cases of transfusion-dependent beta-thalassemia major disease. Materials and methodsThis quasi-experimental study was carried out at District Headquarter Hospital (DHQ), Zhob, from February 2021 to January 2022. One hundred ten cases fulfilling the inclusion-exclusion criteria were selected and divided into groups of 55 each. Group A cases received hydroxyurea (10-20 mg/kg/day) in addition to blood transfusion and chelation therapy. Group B received a blood transfusion and chelation therapy only. Both groups were compared in terms of blood transfusion requirement, mean hemoglobin, and mean serum ferritin levels. All the data were analyzed with SPSS 21 (IBM Corp., Armonk, NY). ResultsOf Group A cases, three were dropped because of side effects of hydroxyurea, and two were lost to follow-up. Similarly, three cases of Group B lost to follow-up, one patient withdrew consent, and one child died at home; thus both groups were left with 50 cases each. The mean age of participants was 11.98 + 3.74 years. There were 51 males and 49 females. Both the groups were comparable in terms of age and gender. Similarly, mean hemoglobin levels and serum ferritin levels were comparable at the start of the study. After one year, there was a significant improvement in mean hemoglobin level (p<0.001) and a significant reduction in serum ferritin levels (p=0.014) in the group taking adjuvant hydroxyurea. The requirement of packed red blood cells (RBCs) significantly decreased in cases taking hydroxyurea (p<0.001). ConclusionHydroxyurea is a safe and effective treatment that significantly decreases the packed RBC transfusion requirement in transfusion-dependent thalassemia children, improves hemoglobin levels, and reduces serum ferritin levels compared to the children on blood transfusions alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan

Akram¹,

Khattak²,

Khan³

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Sources: References [14,17] Three studies compared the change in HbF between two groups. Pooled meta-analysis showed that the mean HbF was higher in patients receiving hydroxyurea; however, the difference was statistically insignificant (MD: 2.24, 95% CI: -0.53, 5.00), as shown in Figure 4.…”

Section: Figure 3: Forest Plot Showing Effect Of Hydroxyurea On Inter...mentioning

confidence: 99%

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis

Hatamleh¹,

Chenna²,

Contractor³

et al. 2023

Cureus

View full text Add to dashboard Cite

The present meta-analysis was conducted to determine the efficacy of hydroxyurea in patients with transfusion dependent major β-thalassemia. The present meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines. A systematic search was carried out to evaluate the efficacy of hydroxyurea in patients with transfusion-dependent B-thalassaemia using electronic databases, including MEDLINE, Cochrane Central Register of Controlled Trials, and EMBASE. The keywords used to search for relevant studies included "hydroxyurea", "thalassemia", "transfusion-dependent", and "efficacy". Outcomes assessed in the present meta-analysis included transfusion in one year and intervals between transfusions (in days). Other outcomes assessed in the present meta-analysis were fetal hemoglobin (%), hemoglobin (%), and ferritin levels (ng/dl). Total of five studies were included in the analysis enrolling 294 patients with major B-thalassemia. The pooled analysis reported that the mean interval between transfusions was significantly higher in patients receiving hydroxyurea compared to those not receiving hydroxyurea (mean deviation {MD}: 10.07, 95% CI: 2.16, 17.99). Hemoglobin was significantly higher in patients receiving hydroxyurea compared to its counterparts (MD: 1.71, 95% CI: 0.84, 2.57). Patients receiving hydroxyurea had significantly lower ferritin levels compared to those not receiving hydroxyurea ). These findings suggest that hydroxyurea may be a promising and cost-effective alternative to blood transfusions and iron chelation therapies for betathalassemia patients. However, the authors noted that further randomized controlled trials are needed to validate these findings and to determine the optimal dosages and treatment regimens for hydroxyurea in this patient population.

show abstract

Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients

Al-Nood

Ghanem

et al. 2020

Hemoglobin

View full text Add to dashboard Cite

Hydroxyurea in Thalassemia Major

Abstract: BACKGROUNDHydroxyurea (HU) is found to be effective in sickle cell anemia and thalassemia intermedia. Its usefulness in thalassemia major is not clearly defined. The aim of the study was to analyze effectiveness of hydroxyurea in children with beta thalassemia major.

Cited by 4 publications

References 12 publications

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan

Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis

Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients

Contact Info

Product

Resources

About